Drug Detail

Information about HQP1351

Generic Name
IND
HQP1351
Brand Name (US)
Manufacturer
Ascentage Pharma
Drug Type
Tyrosine Kinase Inhibitor
Delivery
Oral
Approval Status
Phase 1
Indications
Overall Strategy
KIT Protein Based
Strategy
Block KIT
Drug Category
KIT inhibitor

HQP1351 is a novel kinase inhibitor developed by Ascentage Pharma. It is an oral third-generation BCR-ABL inhibitor targeting a broad spectrum of BCR-ABL mutants, including those with the T315I mutation, to treat drug-resistant CML patients. A Phase I clinical trial for patients with TKI-resistant CML has been completed and the pivotal Phase II clinical trials are ongoing in China. In addition, a Phase Ib trial in patients with GIST and a Phase Ib trial are also ongoing in China and in the U.S., respectively.